Indicated for: cancer
Route of administration: infusion
Substance: mitoxantrone (antineoplastic agent)
ATC: L01DB07 (Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances)
Mitoxantrone is an antineoplastic agent used for the treatment of acute myeloid leukemia, non-Hodgkin's lymphomas, and advanced prostate cancer. It works by intercalating into DNA and inhibiting its synthesis, leading to tumor cell death.
The medication is administered via intravenous infusion, usually in treatment cycles, with the dose adjusted based on the patient's weight and response to therapy. Common side effects include nausea, vomiting, myelosuppression, and alopecia.
Mitoxantrone is contraindicated in patients with severe hepatic impairment or hypersensitivity to the active substance. Its use also requires careful monitoring of cardiac function and blood counts.
This medication is an effective option for the treatment of hematological cancers and other tumor types, helping to improve patient outcomes.